INCYTE CORP 8K

Incyte reported strong Q2 2026 financial results, raised 2026 revenue and expense guidance, recorded a significant one-time Opzelura benefit from a CMS settlement, and announced the acquisition of Vega Therapeutics plus multiple pipeline, regulatory, and collaboration updates.

Incyte Corporation filed a Form 8-K to furnish its second quarter 2026 financial results and business update, reporting a 38% year-over-year increase in total revenue to $1.67 billion and a 40% increase in total net sales to $1.49 billion, driven in part by a one-time, non-cash $246 million benefit tied to a litigation-settlement agreement with CMS over Medicaid rebate rules for Opzelura and broad growth across its hematology, oncology, and inflammation franchises. The company raised its full-year 2026 total net sales guidance to $5.13–$5.26 billion, including higher Opzelura and hematology/oncology sales expectations, and significantly increased GAAP and non-GAAP operating expense guidance to reflect the completed $1.25 billion acquisition of Vega Therapeutics (adding Phase 3 asset latarcibart and an expected $1.27 billion IPR&D charge in Q3 2026) and additional R&D spending. Operationally, Incyte highlighted multiple regulatory and pipeline milestones, including FDA approval of Jakafi XR, CHMP’s positive opinion for Opzelura in moderate atopic dermatitis in Europe, expanded late-stage oncology and hematology trials, a new global collaboration with Halozyme for subcutaneous formulation of INCA033989, a strategic AI collaboration with Edison Scientific and an expanded partnership with Genesis Molecular AI, as well as an exclusive license of zilurgisertib to Mirum Pharmaceuticals, all positioned as supporting the company’s next phase of growth.

Filing Facts

CIK

879169

Ticker

INCY

Form

8K

Source Type

fda

Accession

0000879169-26-000053

Alert Tier

7